Glycoprotein IIb/IIIa Inhibitors Versus Standard Therapy in Patients with Myocardial Infarction and No-reflow

Inclusion Criteria: * ST-elevation myocardial infarction and non-ST-elevation myocardial infarction \<48 h after symptom onset * Angiographic evidence of no-reflow (Thrombolysis in Myocardial Infarction-flow grade ≤2) after primary percutaneous coronary intervention * Age ≥18 years * Informed consent Exclusion Criteria: * ST-elevation myocardial infarction and non-ST-elevation myocardial infarction patients with Thrombolysis in Myocardial Infarction-flow 3 after primary percutaneous coronary intervention * Age ≤18 years * Known pregnancy, breast-feeding or intend to become pregnant during the study period * Contraindication for treatment with platelet inhibitors * Known allergy to glycoprotein IIb/IIIa inhibitors, aspirin, or heparin * Active peptic gastric or duodenal ulcer * History of major surgery (including intracranial or intraspinal) \<4 weeks * Active bleeding or bleeding diathesis * Stroke \<2 years (ischemic and hemorrhagic) * Known coagulation defect or relevant thrombocytopenia * Arteriovenous malformations or aneurysm * Severe liver insufficiency * Renal insufficiency requiring dialysis * Uncontrolled hypertension * Hypertensive retinopathy * Vasculitis * Fibrinolysis \<12 hours * Contraindication for cardiac magnetic resonance imaging at study entry * Patients without informed consent * Participation in another trial